Fig. 1

Characterization of skeletal muscle-derived MPC and MSC by cell surface marker expression and differentiation potential. a Surface expression of mesenchymal (CD105, CD90, CD73), myogenic (CD56), and hematopoietic (CD14, CD19, CD45, CD34, MHCII) lineage markers on both skeletal muscle-derived MPC and MSC assessed by flow cytometry. Data presented as mean ± SD of MPC and MSC from at least three individual muscle biopsies. Statistical comparison was performed by multiple unpaired t tests corrected for multiple testing by Holm-Sidak not assuming consistent SD (corrected p < 0.05 considered significant). b Differentiation potential of MPC and MSC assessed after in vitro differentiation to adipogenic, chondrogenic, osteogenic, and skeletal myogenic lineages by cultivation in respective differentiation media and detected by oil red o, alcian blue, alizarin red s, and anti-desmin/Hoechst staining, respectively. Representative images of at least three individual preparations are shown (scale bar = 100 μm). c Quantification of adipogenic, chondrogenic, osteogenic, and skeletal myogenic differentiation potential of MSC and MPC by calculation of the mean staining intensity per field of oil red o, alcian blue, or alizarin red s staining (how many fields) or by fusion index calculation of at least three individual samples, respectively